ClinicalTrials.gg
Active, not recruitingNCT05243875LEAPUpdated Oct 26, 2026

Lupus Education Alliance Program

An interventional study of LEAP Education + Navigation and LEAP Education in Systemic Lupus Erythematosus and COVID-19, sponsored by Tulane University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Tulane University · Not applicable, Interventional, and Health services research

How we know

Updated Oct 26, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
86th of 407
274 · median 70
Started
2023
with 22 others
No phase
65 of 477
6 open now
Primary completion
2027-01
later than 27 of 125 live
Registered
337th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 86th largest by enrollment of the 407 interventional ones that give a count, is one of 23 that started in 2023, is one of 65 with no phase, reaches primary completion later than 27 of the 125 other live ones, and was the 337th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

Randomized controlled trial of a COVID-19 behavioral and educational intervention for people with systemic lupus erythematosus (SLE).

Read the detailed description

Randomized controlled trial of a COVID-19 behavioral and educational intervention for people with systemic lupus erythematosus (SLE).

03

Conditions studied

  • Systemic Lupus Erythematosus
  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

18 years or older, ability to understand and speak English, diagnosis of SLE

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
274 participants (actual)

Study arms

  • Experimental
    Education / Navigation

    COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE; and (2) navigation, which involves individual tailoring of information about where and how to get tested, and where to get vaccinated, and when appropriate, guiding participants in scheduling testing and vaccination appointments.

    Behavioral: LEAP Education + Navigation

  • Active comparator
    Education Only

    COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE.

    Behavioral: LEAP Education

Interventions

  • BehavioralLEAP Education + Navigation

    COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE; and (2) navigation, which involves individual tailoring of information about where and how to get tested, and where to get vaccinated, and when appropriate, guiding participants in scheduling testing and vaccination appointments.

  • BehavioralLEAP Education

    COVID education involving providing information about COVID for people with SLE and CDC recommendations for testing, testing options (e.g., pharmacies, doctors' offices, at-home), treatment in the event of a positive COVID result, and current recommendations around vaccination for those with SLE.

06

What researchers measure

Primary outcomes

  1. Incidence of COVID testing

    Participant-reported COVID testing

    Time frame: 3 months

  2. Incidence of COVID-19 Vaccination

    Participant-reported COVID vaccination

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be made available to researchers outside the study team after completion of the primary analyses. Data requests, including a list of variables and analytic plan, will be sent to the Project Coordinator and reviewed by the PI, who will approve or deny the data request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jan 2027, 38 months after the start.

Of 123 non-industry interventional studies with no phase under Lupus Erythematosus, Systemic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 38 months is above that.

Counting every sponsor, half of 130 studies reached it within 23 months; a quarter within 10 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Jun 2025 → Jan 2027 and completion Jun 2025 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Feb 17, 2022
StartActual
Nov 1, 2023
Primary completionEst.
Jan 2027was Jun 2025
CompletionEst.
Jan 2027was Jun 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Terminated→Active, not recruiting Reason for stopping removed
changed Oct 26, 2026
Primary completion
Jun 15, 2025→Jan 2027
Oct 26, 2026
Study completion
Jun 15, 2025→Jan 2027
Oct 26, 2026
Sponsor
Collaborators added: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Terminated→Active, not recruiting
    Why stopped Reason for stopping removed
    Primary completion Jun 15, 2025→Jan 2027
    Study completion Jun 15, 2025→Jan 2027
    Sponsor Collaborators added: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    + 3 other changes: identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05243875
Lead sponsor
Tulane University
Collaborators
University of Alabama at Birmingham, Ochsner Health System, Louisiana State University Health Sciences Center in New Orleans, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Nov 1, 2023
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion